Literature DB >> 2324099

RNA editing of apolipoprotein B mRNA. Sequence specificity determined by in vitro coupled transcription editing.

S H Chen1, X X Li, W S Liao, J H Wu, L Chan.   

Abstract

Apolipoprotein (apo) B-48 mRNA is produced by in vivo RNA editing which involves a C----U conversion of the first base of the codon CAA for Gln-2153, changing it to UAA, an in-frame stop codon. We have reproduced the editing reaction in vitro using nuclear extracts. Efficient RNA editing was demonstrated by using apoB mRNA segments as substrate or in a coupled transcription-editing reaction using apoB minigenes as template. ApoB minigenes were constructed by ligating the adenovirus major late promoter to a fragment of apoB-100 DNA containing the editing site and used for the transcription-editing reaction. We defined the sequence specificity of the editing reaction using site-specific single and multiple base mutants constructed by the polymerase chain reaction. Among 22 different mutant apoB-100 minigene constructs containing mutations in the bases immediately flanking the edited C-6666, 20 were edited in the coupled transcription-editing reaction. The results suggest a relatively lax sequence specificity for apoB mRNA editing. Our observation may have important implications for apoB-48 biogenesis as well as for the editing process as a general biologic regulatory mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324099

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  A site-specific factor interacts directly with its cognate RNA editing site in chloroplast transcripts.

Authors:  Tetsuya Miyamoto; Junichi Obokata; Masahiro Sugiura
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-23       Impact factor: 11.205

2.  Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism.

Authors:  J L Casey; K F Bergmann; T L Brown; J L Gerin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

3.  NMR structure of the apoB mRNA stem-loop and its interaction with the C to U editing APOBEC1 complementary factor.

Authors:  Christophe Maris; James Masse; Ann Chester; Naveenan Navaratnam; Frédéric H-T Allain
Journal:  RNA       Date:  2005-02       Impact factor: 4.942

4.  Differences in editing at homologous sites in messenger RNAs from angiosperm mitochondria.

Authors:  P S Covello; M W Gray
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

5.  Characterization of the apolipoprotein B mRNA editing enzyme: no similarity to the proposed mechanism of RNA editing in kinetoplastid protozoa.

Authors:  J Greeve; N Navaratnam; J Scott
Journal:  Nucleic Acids Res       Date:  1991-07-11       Impact factor: 16.971

6.  RNA editing of wheat mitochondrial ATP synthase subunit 9: direct protein and cDNA sequencing.

Authors:  D Bégu; P V Graves; C Domec; G Arselin; S Litvak; A Araya
Journal:  Plant Cell       Date:  1990-12       Impact factor: 11.277

7.  An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3' untranslated region of c-myc increases mRNA stability.

Authors:  S Anant; N O Davidson
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 8.  The biogenesis of chylomicrons.

Authors:  Charles M Mansbach; Shadab A Siddiqi
Journal:  Annu Rev Physiol       Date:  2010       Impact factor: 19.318

9.  Optimization of apolipoprotein B mRNA editing by APOBEC1 apoenzyme and the role of its auxiliary factor, ACF.

Authors:  Ann Chester; Violetta Weinreb; Charles W Carter; Naveenan Navaratnam
Journal:  RNA       Date:  2004-07-23       Impact factor: 4.942

10.  Apolipoprotein B mRNA sequences 3' of the editing site are necessary and sufficient for editing and editosome assembly.

Authors:  J W Backus; H C Smith
Journal:  Nucleic Acids Res       Date:  1991-12-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.